Eton Pharmaceuticals (ETON) Total Current Liabilities (2017 - 2026)

Eton Pharmaceuticals has disclosed Total Current Liabilities across 10 years of filings, most recently posting $45.1 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 16.91% year-over-year to $45.1 million; the TTM figure through Jun 2026 stood at $45.1 million (up 16.91% YoY), while the FY2025 annual figure was $38.5 million, up 92.96% from the prior year.
• Total Current Liabilities came in at $45.1 million for Q2 2026 at Eton Pharmaceuticals, up from $38.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $45.1 million in Q2 2026 to a low of $3.5 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $19.2 million, with a median of $16.2 million recorded in 2023.
• Year-over-year, Total Current Liabilities decreased 13.04% in 2022 and jumped 151.52% in 2023.
• Over 5 years, Total Current Liabilities stood at $6.5 million in 2022, then jumped by 151.37% to $16.2 million in 2023, then increased by 22.82% to $19.9 million in 2024, then jumped by 92.96% to $38.5 million in 2025, then grew by 17.24% to $45.1 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $45.1 million in Q2 2026, $38.5 million in Q4 2025, and $44.2 million in Q3 2025.